{
    "clinical_study": {
        "@rank": "105721", 
        "arm_group": {
            "arm_group_label": "Metformin", 
            "arm_group_type": "Experimental", 
            "description": "Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if metformin will be effective in making endometrial\n      hyperplasia without atypia better by returning the tissue to a normal state."
        }, 
        "brief_title": "Metformin for the Treatment of Endometrial Hyperplasia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Endometrial Hyperplasia", 
            "Endometrial Hyperplasia Without Atypia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-institutional pilot clinical trial designed to estimate the response rate\n      and safety of metformin for the treatment of simple and complex endometrial hyperplasia (EH)\n      without atypia. Enrollment of patients will occur at UNC-Chapel Hill and Southern Pines\n      Women's Health Center. Fifteen patients will be enrolled over the course of 1 year.\n      Metformin will be initiated at 850 mg orally once daily, and titrated up to twice daily over\n      a minimum of 1 months time. Treatment will last 12 weeks and then patients will undergo\n      repeat endometrial biopsy to assess for regression or persistence of EH."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be between the ages of 18-75 years old\n\n          -  Have a confirmed diagnosis of endometrial hyperplasia without atypia based upon\n             endometrial biopsy\n\n          -  Have no contraindications to short-term metformin therapy\n\n          -  Have a creatinine clearance of \u2265 90 ml/min, as calculated by the Cockroft-Gault\n             formula\n\n          -  Have normal serum transaminase values (AST and ALT)\n\n          -  Need to be able to undergo metformin treatment for a duration of 12 weeks prior to\n             repeat endometrial biopsy\n\n        Exclusion Criteria:\n\n          -  Are currently taking metformin or have taken metformin in the past 6 months or have a\n             history of an allergic reaction or intolerance at any time to metformin\n\n          -  Have a history of liver or renal dysfunction.\n\n          -  Have a random glucose of \u2264 65 or \u2265 200\n\n          -  Have a recent history of alcoholism. Former alcoholics who have abstained from\n             alcohol for 5 years or more may be enrolled in this study.\n\n          -  Have a history of vitamin B12 deficiency\n\n          -  Are pregnant\n\n          -  Are currently taking insulin\n\n          -  Are taking a drug that may significantly interact or influence the metabolism of\n             metformin\n\n          -  In the opinion of the investigator, the patient is felt not to be appropriate for the\n             study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685762", 
            "org_study_id": "LCCC 1205"
        }, 
        "intervention": {
            "arm_group_label": "Metformin", 
            "description": "850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).", 
            "intervention_name": "Metformin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Fortamet", 
                "Glucophage", 
                "Glumetza", 
                "Riomet"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Endometrial hyperplasia", 
            "Uterus", 
            "Pilot", 
            "Metformin"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "link": {
            "description": "UNC Lineberger Comprehensive Cancer Center", 
            "url": "http://unclineberger.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "mark_bozymski@med.unc.edu", 
                    "last_name": "Mark Bozymski", 
                    "phone": "919-966-4432"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "The University of North Carolina at Chapel Hill"
                }, 
                "investigator": [
                    {
                        "last_name": "Victoria Bae-Jump", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Emily Ko, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southern Pines", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28388"
                    }, 
                    "name": "Southern Pines Women's Health Center"
                }, 
                "investigator": {
                    "last_name": "John Byron, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Emily Ko, MD, MSCR", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Metformin for the Treatment of Endometrial Hyperplasia", 
        "overall_contact": {
            "email": "mark_bozymski@med.unc.edu", 
            "last_name": "Mark Bozymski", 
            "phone": "919-966-4432"
        }, 
        "overall_contact_backup": {
            "email": "donna_rowe@med.unc.edu", 
            "last_name": "Donna Rowe, RN", 
            "phone": "919-966-7359"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Victoria Bae-Jump, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of hyperplasia resolution by comparison of pre- and post-treatment endometrial biopsies.", 
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of subjects who experience side effects", 
                "measure": "Toxicity evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Percentage of patients successfully completing metformin therapy.", 
                "measure": "Patient Compliance", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Compare changes in potential biomarkers, including metabolic factors and molecular markers of downstream targets of the metformin/mTOR signaling pathway, before and after metformin treatment.", 
                "measure": "Potential molecular markers in response to treatment with Metformin", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}